The commercial launch of a new blood cancer test for patients with B- and T-cell lymphomas took place during the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, Texas. The manufacturer of the test, Arima Genomics, hopes that the test will help guide clinicians to a clearer diagnosis.
“Our goal is to reduce blind spots in lymphoma diagnosis by offering an ultra-sensitive test that uncovers the full spectrum of clinically meaningful rearrangements—whether or not they are initially considered,” said Chris Roberts, chief product officer for Arima Genomics and executive director for the Aventa clinical testing service, in a press release by the company.
The Aventa Lymphoma test analyzes 417 genes in a single whole-genome assay, detecting gene fusions and rearrangements missed by traditional fluorescence in situ hybridization (FISH). It conserves tissue and clarifies ambiguous diagnoses for better lymphoma classification and treatment planning, according to Arima Genomics.
“The Aventa Lymphoma test can uncover gene fusions and rearrangements that may be missed by traditional FISH testing, ensuring clinically significant abnormalities are not overlooked. This transformative tool enhances patient care,” said Ying Zou, MD, PhD, the director of the Cancer Cytogenetic Laboratory, Cytogenomic Research Core and associate director of the Molecular Diagnostics Laboratory at Johns Hopkins University. “In lymphomas exhibiting atypical FISH signal patterns across multiple biomarkers, the Aventa Lymphoma test identified actionable genetic alterations, significantly enhancing diagnostic precision, subtype classification, prognostic evaluation, and tailored treatment strategies.”
The test is offered through Arima’s CLIA-certified laboratory, and the test received Proprietary Laboratory Analysis (PLA) code 0592U from the American Medical Association.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
